Reader Comments on "A Tale of Two Pharmaceutical Industries" - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Reader Comments on "A Tale of Two Pharmaceutical Industries"


The comment below is in response to Editor-in-Chief Michelle Hoffman's December 2008 editorial, “A Tale of Two Pharmacetuical Industries.”

Reader H.Y. Guh writes:

Your recent article in Pharmaceutical Technology about two pharmaceutical industries, one for export and one for the domestic, in China is absolutely correct. Having been consulting in China over the past 7 years, however, I am in disagreement on the regulations by the Chinese government.
 
The State Drug and Food Administration (SFDA), a government agency in Beijing, regulates the pharmaceutical industry in a way similar to that of the FDA. As a matter of fact, the SFDA has literally copied  US GMP practices and regulations for its use.
 
The sad part is inadequate enforcement due to rampant corruptions at all levels of the agency. During visits to my clients, I have observed personally how an inspection was conducted and managed. Furthermore, the market place is chaotic, “anything goes”, and full of bribery and kickbacks. Hospitals and medical professionals rely heavily on the “gray” drug income to maintain services and livelihood. For instance, a skilled surgeon makes a meager salary of about 3,000 Yuan (or US$450) a month, less than a college graduate of 2-3 year experience. The thin profit margins have made it economically impossible for pharmaceutical companies to follow GMP. For overseas markets of good margins, Chinese firms can afford to meet GMP requirements acceptable to the FDA or other foreign agencies.
 
As an overseas Chinese, I feel horrible about the poor pharmaceutical quality that Chinese people are getting. From a pragmatic standpoint, China lacks resources to manage all of its needs demanded by 1.3 billion citizens. Its leaders have to make tough choices. Drug quality unfortunately commands less priority when compared to food safety.
 
On the positive side, China is rapidly evolving and is moving toward an open society day by day. I hope in the not too distant future, the SFDA would attain adequate funding, strengthen enforcement and do away with the 2-tier system.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here